title: Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab.
abstract: BACKGROUND
  Regulatory approval for a biosimilar product is provided on the basis of its comparability to an originator product. A thorough physicochemical and functional comparability exercise is a key element in demonstrating biosimilarity. Here we report the characterization of a proposed biosimilar rituximab (GP2013) and originator rituximab.
  
  
  OBJECTIVE
  To compare GP2013 with originator rituximab using an extensive array of routine analytical and extended characterization methods.
  
  
  METHODS
  Primary and higher order protein structures were analyzed using a variety of methods that included high-performance liquid chromatography electrospray ionization mass spectrometry (HPLC-ESI-MS), peptide mapping with UV and MS detection, circular dichroism (CD), Fourier transform infrared (FTIR) spectroscopy, hydrogen deuterium exchange (HDX) MS, 1D (1)H nuclear magnetic resonance (NMR) spectroscopy, X-ray crystallography and differential scanning calorimetry (DSC). Charge and amino acid modifications were assessed using cation exchange chromatography (CEX) and peptide mapping using reversed-phase (RP) HPLC. Boronate affinity chromatography was used to determine the relative amount of glycation. Glycans were identified and quantified after 2-aminobenzamide (2-AB) labeling and separation using normal phase HPLC with fluorescence and MS detection, respectively. Glycan site occupancy was determined using reducing capillary electrophoresis with sodium dodecyl sulfate (CE-SDS). Size heterogeneity was determined using reducing and non-reducing CE-SDS, size exclusion chromatography (SEC) and asymmetric flow field flow fractionation (AF4). Biological characterization included a series of bioassays (in vitro target binding, antibody-dependent cell-mediated cytotoxicity [ADCC], complement-dependent cytotoxicity [CDC] and apoptosis) and surface plasmon resonance (SPR) Fc receptor binding assays.
  
  
  RESULTS
  Intact mass analysis of GP2013 and the heavy and light chains using RP HPLC-ESI-MS revealed the expected molecular mass of rituximab. The amino acid sequence was shown to be identical between GP2013 and the originator rituximab. Further sequence confirmation using RP-HPLC-UV/MS peptide mapping showed non-distinguishable chromatograms for Lys-C digested GP2013 and originator rituximab. The higher order structure of GP2013 was shown to be indistinguishable from originator rituximab using a large panel of redundant and orthogonal methods. GP2013 and originator rituximab were comparable with regard to charge variants, specific amino acid modifications and the glycan pattern. GP2013 was also shown to have similar purity, aggregate and particle levels when compared with the originator. Functionally, and by using a comprehensive set of bioassays and binding assays covering a broad range of rituximab's functional activities, GP2013 could not be distinguished from originator rituximab.
  
  
  CONCLUSIONS
  GP2013 was shown to be physicochemically highly similar to originator rituximab at the level of primary and higher order structure, post-translational modifications and size variants. An extensive functional characterization package indicated that GP2013 has the same biological properties as originator rituximab.
authors: Sandoz Biopharmaceuticals, Hexal AG, Keltenring 1 + 3, 82041, Oberhaching, Germany, jan_marinus.visser@sandoz.com.
authors: Jan
authors: J
authors: Visser
authors: Isabel
authors: I
authors: Feuerstein
authors: Thomas
authors: T
authors: Stangler
authors: Timo
authors: T
authors: Schmiederer
authors: Cornelius
authors: C
authors: Fritsch
authors: Martin
authors: M
authors: Schiestl
mesh_terms: D000595:Amino Acid Sequence; D058846:Antibodies, Monoclonal, Murine-Derived / Q000737:chemistry* / Q000494:pharmacology*; D059451:Biosimilar Pharmaceuticals / Q000737:chemistry* / Q000494:pharmacology*; D002460:Cell Line; D006801:Humans; D007694:Killer Cells, Natural / Q000187:drug effects; D010449:Peptide Mapping / Q000379:methods; D011134:Polysaccharides / Q000737:chemistry; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D059451:Biosimilar Pharmaceuticals; D011134:Polysaccharides; D000069283:Rituximab
references: MAbs. 2010 Nov-Dec;2(6):613-24
references: 20818176
references: Nat Biotechnol. 2010 Aug;28(8):863-7
references: 20657583
references: J Pharm Sci. 2011 Jun;100(6):2071-86
references: 21491437
references: Protein Expr Purif. 2010 May;71(1):42-8
references: 20006709
references: Nat Rev Immunol. 2007 Sep;7(9):715-25
references: 17703228
references: Biochim Biophys Acta. 2008 Feb;1780(2):75-88
references: 18047841
references: Anal Chem. 2009 Oct 1;81(19):7870-5
references: 19788312
references: AAPS J. 2006 Aug 04;8(3):E501-7
references: 17025268
references: Semin Hematol. 2010 Apr;47(2):115-23
references: 20350658
references: Protein Sci. 2010 Feb;19(2):279-90
references: 20014440
references: Target Oncol. 2012 Mar;7 Suppl 1:S57-67
references: 22249658
references: Anal Biochem. 2007 Jan 1;360(1):75-83
references: 17113563
references: J Chromatogr B Analyt Technol Biomed Life Sci. 2007 May 1;850(1-2):285-94
references: 17182291
references: J Immunol Methods. 2005 Nov 30;306(1-2):151-60
references: 16219319
references: Anal Chem. 2005 Sep 15;77(18):6004-11
references: 16159134
references: Curr Pharm Biotechnol. 2008 Dec;9(6):482-501
references: 19075687
references: J Biol Chem. 2001 Dec 7;276(49):45539-47
references: 11567028
references: Blood. 2002 Feb 1;99(3):754-8
references: 11806974
references: Mol Immunol. 2007 May;44(12):3122-31
references: 17379311
references: Glycobiology. 2009 Sep;19(9):936-49
references: 19494347
references: Nat Biotechnol. 2011 Apr;29(4):310-2
references: 21478841
references: Pharm Res. 2011 Apr;28(4):920-33
references: 20972611
references: N Engl J Med. 2008 Mar 13;358(11):1109-17
references: 18337601
references: Clin Pharmacol Ther. 2012 Mar;91(3):405-17
references: 22318617
references: Annu Rev Immunol. 2008;26:513-33
references: 18370923
references: Nat Rev Drug Discov. 2011 Feb;10(2):101-11
references: 21283105
references: MAbs. 2012 May-Jun;4(3):326-40
references: 22531441
references: J Biol Chem. 2002 Jul 26;277(30):26733-40
references: 11986321
references: Anal Chem. 2008 Apr 1;80(7):2379-90
references: 18307322
references: MAbs. 2012 Sep-Oct;4(5):578-85
references: 22820257